Addition of aprepitant may improve vomiting control in patients receiving oxaliplatin
the ONA take:
According to results presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have found that a three-drug combination antiemetic therapy including aprepitant or fosaprepitant significantly improved the prevention rate of nausea and vomiting in patients receiving oxaliplatin chemotherapy.
For the multicenter, open-label, phase III SENRI Trial, researchers enrolled 413 Japanese patients with colorectal cancer who were receiving oxaliplatin-based chemotherapy. Patients were randomly assigned 1:1 to receive a 5-HT3 receptor antagonist plus dexamethasone with or without aprepitant or fosaprepitant during the first course of chemotherapy. All patients received aprepitant or fosaprepitant in subsequent courses.
Results showed that significantly more patients who received an NK1 antagonist achieved no vomiting overall and no vomiting in the delayed phase than those in the control arm. Researchers also found that women had higher rates of no nausea and complete protection in the aprepitant arm than the control arm.
The standard protocol for prevention of chemotherapy-induced nausea and vomiting in patients receiving oxaliplatin-based chemotherapy is a 5-HT3 receptor antagonist plus dexamethasone.
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|